• Eli Lilly agreed to buy Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious-disease vaccine and prevention pipeline.
• Curevo deal values payments at up to USD 1.5 billion, centered on a Phase 2 shingles vaccine candidate designed to improve tolerability.
• LimmaTech acquisition totals up to USD 780 million, adding early-stage bacterial vaccine programs including a Phase 1 Staphylococcus aureus candidate.
• Vaccine Company transaction totals up to USD 1.55 billion, bringing an in vivo nanoparticle platform and an EBV vaccine candidate described as Phase 1-ready.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE67396) on May 26, 2026, and is solely responsible for the information contained therein.